Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

But CRISPR is a long-term story that is still in the early innings. The company has moved past its proof-of-concept phase, ...

A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...

China research team at Wuhan University of Science and Technology uses CRISPR to remove HIV DNA from human cells, marking a potential breakthrough in treatment.

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

Researchers developed a CRISPR-based system that spreads through bacterial populations to disable antibiotic resistance genes ...

Scientists in China report removing HIV from human DNA using gene-editing technology. Experts say the findings are promising but still far from a confirmed cure.

Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...

Researchers used CRISPR gene editing to selectively kill cancer cells with amplified oncogenes. In animal and cellular models ...